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Abstract
Background:  The aim of the study was to assess the chronic effects of combined
phosphodiesterase 3/4 inhibitor tolafentrine, administered by inhalation, during monocrotaline-
induced pulmonary arterial hypertension (PAH) in rats.
Methods: CD rats were given a single subcutaneous injection of monocrotaline to induce PAH.
Four weeks after, rats were subjected to inhalation of tolafentrine or sham nebulization in an
unrestrained, whole body aerosol exposure system. In these animals (i) the acute pulmonary
vasodilatory efficacy of inhaled tolafentrine (ii) the anti-remodeling effect of long-term inhalation of
tolafentrine (iii) the effects of tolafentrine on the expression profile of 96 genes encoding cell
adhesion and extracellular matrix regulation were examined. In addition, the inhibitory effect of
tolafentrine on ex vivo isolated pulmonary artery SMC cell migration was also investigated.
Results:  Monocrotaline injection provoked severe PAH (right ventricular systolic pressure
increased from 25.9 ± 4.0 to 68.9 ± 3.2 after 4 weeks and 74.9 ± 5.1 mmHg after 6 weeks), cardiac
output depression and right heart hypertrophy. The media thickness of the pulmonary arteries and
the proportion of muscularization of small precapillary resistance vessels increased dramatically,
and the migratory response of ex-vivo isolated pulmonary artery smooth muscle cells (PASMC)
was increased. Micro-arrays and subsequent confirmation with real time PCR demonstrated
upregulation of several extracellular matrix regulation and adhesion genes, such as
matrixmetalloproteases (MMP) 2, 8, 9, 10, 11, 12, 20, Icam, Itgax, Plat and serpinb2. When
chronically nebulized from day 28 to 42 (12 daily aerosol maneuvers), after full establishment of
severe pulmonary hypertension, tolafentrine reversed about 60% of all hemodynamic
abnormalities, right heart hypertrophy and monocrotaline-induced structural lung vascular changes,
including the proportion of pulmonary artery muscularization. The upregulation of extracellular
Published: 01 November 2005
Respiratory Research 2005, 6:128 doi:10.1186/1465-9921-6-128
Received: 17 August 2005
Accepted: 01 November 2005
This article is available from: http://respiratory-research.com/content/6/1/128
© 2005 Pullamsetti et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
Page 2 of 14
(page number not for citation purposes)
matrix regulation and adhesion genes was reduced by nearly 80% by inhalation of the tolafentrine.
When assessed in vitro, tolafentrine blocked the enhanced PASMC migratory response.
Conclusion: In conclusion, we demonstrate for the first time that inhalation of combined PDE3/
4 inhibitor reverses pulmonary hypertension fully developed in response to monocrotaline in rats.
This "reverse-remodeling" effect includes structural changes in the lung vascular wall and key
molecular pathways of matrix regulation, concomitant with 60% normalization of hemodynamics.
Background
Pulmonary arterial hypertension (PAH) is a severe disa-
bling disease characterized by elevation of pulmonary
artery pressure and death attributable to right heart failure
[1]. It is a progressive, proliferative vascular disorder
resulting from persistent vasoconstriction and structural
remodeling of pulmonary vessels. The structural changes
include endothelial cell injury, neovascularization of
small arteries, smooth muscle cell (SMC) migration and
proliferation, and abnormal accumulation of extracellular
matrix proteins associated with activation of matrix met-
alloproteinases (MMPs) [2].
The MMPs are a family of matrix-degrading enzymes that
have been implicated in two important processes in vessel
wall repair: cellular migration [3], and regulating extracel-
lular matrix composition and content [4]. Based on their
substrate specificity, MMPs were subdivided into four
groups: i) interstitial collagenases (MMP 1, MMP 8 and
MMP 13) that degrade fibrillary collagens; ii) type IV col-
lagenases (MMP 2 and MMP 9) that degrade basement
membrane components; iii) stromelysins (MMP 3, MMP
10 and MMP 11) that degrade proteoglycans, fibronectin,
laminin, gelatin and the globular proteins of the type IV
collagen; and iv) membrane type-MMPs (MT-1, MMP 15,
MMP 16 and MMP 17), possessing a broad spectrum of
activities.
Of the MMPs, expression of MMP 2 and MMP 9 in partic-
ular, which degrade type IV collagen of basement mem-
branes, are increased in the pulmonary vascular bed,
during both monocrotaline (MCT) and hypoxia-induced
experimental PAH [5]. In addition, MMP 1, an interstitial
collagenase, is upregulated in MCT-induced PAH [6]. In
recent years, several pharmacological interventions in
PAH, including MMP inhibitors, endothelin antagonist,
angiotensinogen inhibitors and phosphodiesterase (PDE)
inhibitors that target either the MMP cascades or endog-
enous vascular elastases, proved to be beneficial in exper-
imental PAH models, with most of these agents being
applied prior to full establishment of the disease [7-11].
Suppression of vessel wall remodeling was assumed to
largely contribute to these beneficial effects.
The phosphodiesterases (PDEs) are a large family of intra-
cellular enzymes that degrade cyclic nucleotides [12,13].
Because of their potential for altering a variety of cellular
responses, PDEs are appealing targets for the treatment of
PAH [14,15]. Phosphodiesterase 3 and 4 isoenzymes are
the essential players co-regulating cAMP catabolism in
many organs, including the lung, and were shown to be
upregulated in experimental PAH models. Inhibitors of
PDE 3 and 4 synergistically promoted the acute pulmo-
nary vasodilation evoked by prostacyclin or its stable ana-
logues in experimental models of PAH [16-18]. Recently,
inhalation of the combined -selective PDE3/4 inhibitor
tolafentrine has been shown to amplify the vasodilatory
effect of inhaled iloprost in patients with PAH [18]. How-
ever, no data are currently available regarding effects of
long-term inhalation of tolafentrine on hemodynamics
and pulmonary vascular remodeling in PAH models.
In the present investigation, we employed monocrotaline
(MCT), a toxin derived from plants of the Crotalaria spe-
cies [19], for pulmonary artery smooth muscle cell hyper-
trophy and severe pulmonary hypertension in rats [20]. In
this model we examined (i) the acute pulmonary
vasodilatory efficacy of inhaled tolafentrine (ii) the anti-
remodeling effect of long-term inhalation of tolafentrine
(iii) the inhibitory effect of tolafentrine on pulmonary
artery SMC cell migration, and (iv) the effect of the PDE
inhibitor on the expression profile of 96 genes encoding
cell adhesion and extracellular matrix regulation. To
mimic clinical conditions, inhalation of tolafentrine com-
menced after pulmonary hypertension was already fully
established. Essentially, we found that inhaled tolafen-
trine reverses hemodynamic abnormalities as well as
structural changes, SMC migration and proliferation and




Experiments were performed on male CD rats 300 – 350
g body weight, Charles River, Sulzfeld, Germany). Pulmo-
nary hypertension was induced by a single subcutaneous
injection of monocrotaline (MCT, 60 mg/kg, Sigma,
Deishofen, Germany), dissolved in 0.1 M NaOH, adjusted
to pH 7.4 with 0.1 M HCl, according to the previous
reports [7,10,21,22].Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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The experiments were performed in accordance with the
National Institutes of Health Guidelines on the Use of
Laboratory Animals. Both the University Animal Care
Committee and the Federal Authorities for Animal
Research of the Regierungspräsidium Giessen (Hessen,
Germany) approved the study protocol.
Study groups
The animals were classified into the following four
groups: 1) rats injected with saline sacrificed after 28 days
(Control, n = 8); 2) MCT-injected rats sacrificed after 28
days (MCT[28d], n = 12); 3) MCT-injected sacrificed after
42 days, with nebulized vehicle being administered from
day 28 to day 42 (MCT[42d], n = 14); 4) MCT-injected rats
sacrificed after 42 days, with nebulized tolafentrine being
administered from day 28 to day 42 (MCT[42d]/Tola, n =
10). For acute hemodynamic studies 12 MCT[28d] rats
(MCT injected for 28 days) were used (inhalation of
saline, n = 6; and inhalation of tolafentrine in two differ-
ent doses, n = 6 each).
Inhalation of tolafentrine
Four weeks after a single MCT injection, rats were sub-
jected to inhalation of tolafentrine or sham nebulization
in an unrestrained, whole body aerosol exposure system
as described [23]. For assessment of chronic effects of
inhaled saline or tolafentrine (dose deposited in the lungs
~ 120 µg/kg day), 15 min nebulization maneuvers using a
jet nebulizer with a constant flow rate of 6 l/min (Pari LC
Star, Pari, Starnberg, Germany) were repeated twelve
times per day for 2 weeks (day 28 – 42). Particles gener-
ated by the jet nebulizer were characterized by a mass
median aerodynamic diameter (MMAD) of 2.8 µm and a
geometric standard deviation (GSD) of 2.5 (determined
by laser difractometric measurements, as described [24].
Preliminary experiments with nebulization of 99Tc-DTPA
determined the total lung deposition of nebulized mate-
rial to range at 0.5 %, in accordance with previous studies
in this model [22].
To assess the acute effects of inhaled tolafentrine, hemo-
dynamic testing in response to the drug was performed in
animals that had previously received a MCT injection 4
weeks prior to study. Hemodynamics were measured
before and after a single inhalation of the tolafentrine
(130 and 650 µg/kg min for 10 min) by an ultrasonic neb-
ulizer with MMAD of 4.0 µm and GSD of 2.1 as described
previously [22,23,25].
Surgical Preparation, measurement of hemodynamics and 
tissue preparation
For measurement of hemodynamic parameters, rats were
anaesthetized with an i.p. injection of ketamine (9 mg/kg
body mass) and medetomidine (100 µg/kg body mass),
followed by an i.m. injection of atropine (250 µg/kg body
mass). The rats were tracheotomized and ventilated with
a frequency of 60 breaths/min. Positive end expiratory
pressure was set at 1 cm H2O. A polyethylene catheter was
inserted into the left carotid artery to measure arterial
pressure. A right heart catheter (PE 50 tubing) was
inserted into the right ventricle through the right jugular
vein for measurement of right ventricular systolic pressure
with fluid-filled force transducers [10,11]. Cardiac output
(CO) was measured by thermodilution technique as
described [10,11]. Briefly, a thermistor (1.5 F) was placed
into the ascending thoracic aorta via the right carotid
artery for the measurement of transpulmonary thermodi-
lution cardiac output (Cardiotherm 500-X, Hugo-Sachs
Electronic – Harvard Apparatus GmbH, March-Hugstet-
ten, Germany). The CO was averaged from three consecu-
tive determinations and indexed to the weight of the
animal to obtain cardiac index (CI). After exsanguination,
the left lung was fixed for histology in 10% neutral buff-
ered formalin and the right lung was snap frozen in liquid
nitrogen.
Immediate vasodilatory effects of inhaled tolafentrine in  monocrotaline-induced pulmonary arterial hypertension Figure 1
Immediate vasodilatory effects of inhaled tolafen-
trine in monocrotaline-induced pulmonary arterial 
hypertension. Monocrotaline (MCT[28d]) treated animals 
received tolafentrine over an inhalation period of 5 min sub-
sequent to catheterization. The decrease in right ventricular 
systolic pressure (RVSP, in mmHg) and systemic arterial 
pressure (SAP, in mmHg) in response to the vasodilatory 
treatment is given. All values are given as mean ± SEM. *, p < 
0.05 versus non treated animalsRespiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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Right ventricular hypertrophy
The RV was dissected from the left ventricle (LV) and the
septum (S) and weighed to determine the extent of RV
hypertrophy as follows: RV/ (LV+S).
Histological examination of the lungs
Paraffin lung sections (3 µm) were double-stained with
anti-α-smooth muscle actin antibody (dilution 1:900,
clone 1A4, Sigma, Saint Louis, Missouri) and anti-human
von Willebrand factor antibody (vWF, dilution 1:900,
Dako, Hamburg, Germany). Sections were counterstained
with hematoxylin and examined by light microscopy
using a computerized morphometric system (Qwin, Leica,
and Wetzlar, Germany) for assessing the degree of muscu-
larization of small peripheral pulmonary arteries
[10,11,23]. In addition, lung sections were stained for
Elastin-Nuclear Fast Red to assess the medial wall thick-
ness.
Categorization of pulmonary arteries based on the degree
of muscularization and on the external diameter and the
percentage of medial wall thickness were performed as
previously described [10,11,23].
Microarray and data analysis
Total RNA extraction was performed using the Trizol rea-
gent (Burlington, Ontario, Canada) according to the
instructions given by the manufacturer from control,
monocrotaline (MCT[42d]) and monocrotaline plus tolaf-
entrine (MCT[42d]/Tola) treated lungs. Samples were
treated with DNase I according to the RNase-free DNase
set (QIAGEN, Hilden, Germany). Total RNA (5 µg) from
each sample was used to generate Biotin-16-dUTP labeled
cDNA and hybridized to the extracellular matrix and
adhesion molecules gene array (GEArray Q series, Super-
array, MD, USA). After hybridization, the membranes
were developed according to the manufacturer's recom-
mendations to yield luminescent signals, which were then
captured on X-ray film.
The resulting image data were analyzed for differential
gene expression patterns using GE Array Analyzer 1.2
(Super Array Bioscience Corp., Frederick, MD) software.
Loading was adjusted on the basis of the intensity of
hybridization signals relative to the housekeeping gene
GAPDH.
Real-time polymerase chain reaction
Quantitative real-time PCR was performed as described
[26]. Briefly, total RNA was isolated from frozen lungs
using Trizol Reagent according to the manufacturer's
instructions. For the generation of cDNA, equal amounts
of RNA from each sample were used as templates for
reverse transcription of first-strand cDNA using the
qPCR™ Mastermix (Euro-genetec, Seraing, Belgium)
according to the manufacturer's protocol. For quantitative
real-time RT-PCR analysis, 2 µl cDNA was placed into 50
µl reaction volume containing SYBR Green PCR mix and
sequence-specific oligonucleotide primers. The thermal
cycle conditions used for all reactions were as follows:
activation, 50°C for 2 min; denaturation, 95°C for 10
min; and cycle, 95°C for 10 s and 60°C for 5 s (40 times).
Specific primers used for sequence detection were:
rGAPDH,5'-GTG ATG GGT GTG AAC CAC GAG-3' (for-
ward) and5'-CCA CGA TGC CAA AGT TGT CA-
3'(reverse); forMMP2,5'-ATC TGC AAG CAA GAC ATT
GTC TT-3'(forward)and 5'-GCC AAA TAA ACC GAT CCT
Influence of inhaled tolafentrine on hemodynamics in  monocrotaline – induced pulmonary arterial hypertension Figure 2
Influence of inhaled tolafentrine on hemodynamics in 
monocrotaline – induced pulmonary arterial hyper-
tension. Right ventricular systolic pressure (RVSP, in 
mmHg), systemic arterial pressure (SAP, in mmHg), cardiac 
index (CI, in ml min-1 100 g body weight-1) and total pulmo-
nary resistance index (PRI, in mmHg min ml-1 100 g body 
weight-1) are given. Tolafentrine was applied by repetitive 
inhalations from day 28 to day 42. All values are given as 
mean ± SEM. *, p < 0.05 versus control; †, p < 0.05 versus 
MCT[28d]; ‡, p < 0.05 versus MCT[42d].Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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TGA A-3' (reverse);for MMP8, 5'-CGG GAA GAC ATA CTC
TTC GAA-3'(forward)and 5'-CAT GGA TCT TCT TTG ATT
GTC G-3' (reverse);for MMP9, 5'-GTA ACC CTG GTC ACC
GGA CTT -3'(forward)and 5'-ATA CGT TCC CGG CTG
ATC AG-3' (reverse); for MMP10, 5'- GGA GAT GCT CAC
TTC GAT GAT-3' (forward)and 5'-CAG CAA CCA GGA
ATA AAT TGG-3' (reverse); for MMP11, 5'-TTC TGA GAT
TGA TGC TGC TTT C-3'(forward)and 5'-TGT CCA CGA
AGG AAG TAG GC-3' (reverse); for MMP12, 5'-GCT GTC
ACA ACA GTG GGA GA-3' (forward)and 5'-GTA ATG TTG
GTG GCT GGA CTC-3' (reverse); for MMP20, 5'-GAA TAA
ACT CTG GGG AAG CAG A-3'(forward)and 5'-TGA TTG
GAT TAA GGC CTC GT-3' (reverse); for Icam, 5'-CAG CTG
CGC TGT GTT TTG-3'(forward)and 5'-GGA TGG GAG
CTG AAA AGT TG-3' (reverse); For Itgax, 5'-GCC TCG
AGA CTG GAG ATC AT-3'(forward)and 5'-GGA GAG CTG
GGA GCC AGT-3' (reverse);for Ncam1, 5'-ACC ATG AGC
TGG ACA AAG GA-3'(forward)and 5'-CAC TGA AGA TGT
GCT TCT CGT C-3' (reverse); for Plat, 5'-AAT GAA GGG
AGA GCT GTT GTG-3'(forward) and 5'-TCC TCT TCT
GAA CCT CCT GTG-3' (reverse); for Serpinb2, 5'-CGA
AAG GGA TTT TGT GAT GTC-3' (forward)and 5'-GTG
GGA AAT GGG AAT TCG T-3' (reverse). All real-time reac-
tions were carried on an ABI 7700 sequence Detection
System (Applied Biosystems, Foster City, CA, USA), and
analysis was performed with the accompanying software.
At the end of the PCR cycle, a dissociation curve was gen-
erated to ensure the amplification of a single product and
the threshold cycle time (Ct values) for each gene was
determined. Relative mRNA levels were calculated based
on the Ct values and normalized to house keeping gene
GAPDH.
Migration assay
Pulmonary artery smooth muscle cell (PASMC) migration
was examined in Transwell cell culture chambers with gel-
atin-coated polycarbonate membranes as described previ-
ously [27]. For this assay, control and MCT-treated rat
PASMCs were isolated and added to the upper well of a
Transwell (Corning Costar, Cambridge, MA) at 2 × 105
cells/well. The platelet-derived growth factor – BB (PDGF-
BB) was added to the lower chamber at a concentration of
25 ng/ml and cells were allowed to migrate for 8 and 24
hours. In experiments with the combined selective PDE3/
4 inhibitor tolafentrine (0.05, 0.1 and 0.3 µM), MCT-
treated rat PASMCs were pre-incubated with tolafentrine
in the upper well of a Transwell for 30 min before the
addition of PDGF-BB into the lower chamber. Migration
was quantified by staining the cells with crystal violet
(Sigma, Deishofen, Germany) following microscopic cell
counts on five random fields in each well. Experiments
were performed in triplicate and were repeated at least
three times.
Data analysis
All data are given as mean ± SEM. Differences between the
groups were assessed by analysis of variance (one-way
ANOVA) and Student-Newman-Keuls test for multiple
comparisons with a p value < 0.05 regarded to be signifi-
cant.
Results
Acute vasodilatory effects of aerosolized tolafentrine in 
MCT treated (28d) rats
Aerosolized tolafentrine reduced right ventricular systolic
pressure [RVSP] in MCT[28d]  rats in a dose-dependent
manner (Figure 1). As depicted, this pulmonary vasodila-
tation was accompanied by less pronounced decrease in
systemic arterial pressure.
Chronic effects of aerosolized tolafentrine: hemodynamics
After injection of monocrotaline, pulmonary hyperten-
sion developed (right ventricular systolic pressure on day
28 = 66.5 ± 3.2 mm Hg (n = 11) and on day 42 = 74.9 ±
5.1 mm Hg (n = 9), as compared to 25.9 ± 4.0 mm Hg in
the control animals (n = 10)) (Figure 2). No significant
changes in systemic arterial pressure occurred. As com-
pared to control animals (36.5 ± 3.5 ml/min 100 g body
weight), cardiac index was slightly decreased on day 28
(31.8 ± 1.3 ml/min/100 g body weight) and significantly
decreased on day 42 (28.1 ± 2.5 ml/min/100 g body
weight). Aerosolized tolafentrine treatment significantly
lowered right ventricular pressure to 48.4 ± 2.1 mmHg (p
< 0.05 versus MCT[42d]  and MCT[28d]). No significant
changes in systemic arterial pressure occurred in animals
undergoing long-term tolafentrine inhalation (n = 8),
while cardiac output was significantly increased in the
MCT[42d]/Tola group.(42.1 ± 5.1 ml/min/100 g body
Influence of inhaled tolafentrine on right heart hypertrophy Figure 3
Influence of inhaled tolafentrine on right heart hyper-
trophy. Right to left ventricular plus septum ratio (RV/
LV+S) of different treatment groups is given. Tolafentrine 
was applied by repetitive inhalations from day 28 to day 42. 
All values are given as mean ± SEM. *, p < 0.05 versus con-
trol; †, p < 0.05 versus MCT[28d]; ‡, p < 0.05 versus MCT[42d].Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
Page 6 of 14
(page number not for citation purposes)
weight; p < 0.05 versus MCT[42d]). The total pulmonary
resistance index, calculated from the RVSP and cardiac
output values, was even fully normalized in the MCT[42d]/
Tola animals.
Chronic effects of aerosolized tolafentrine: right 
ventricular hypertrophy
Four weeks after injection of MCT, animals demonstrated
significant right heart hypertrophy, as indicated by an
Effect of inhaled tolafentrine on the degree of muscularization and on the medial wall thickness of small pulmonary arteries Figure 4
Effect of inhaled tolafentrine on the degree of muscularization and on the medial wall thickness of small pul-
monary arteries. Immunohistochemical analysis of lung sections originating from saline (Control), monocrotaline (MCT[42d]) 
and monocrotaline plus tolafentrine (MCT[42d]/Tola) treated animals. Staining was undertaken for von Willebrand-factor 
(brown; endothelial cells) and alpha smooth muscle actin (purple; smooth muscel cells) as well as elastin. Scale bar: 20 µm.Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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increase in the right ventricular to left ventricular plus sep-
tum weight ratio (RV/LV+S) from 0.29 ± 0.02 (control
animals) to 0.60 ± 0.02 (Figure 3). Rats that received
inhaled vehicle for 2 weeks demonstrated further progres-
sion of right ventricular hypertrophy (RV/LV+S = 0.71 ±
0.05). Inhaled tolafentrine reversed established right ven-
tricular hypertrophy (MCT[42d]/Tola = 0.47 ± 0.03; p <
0.05 versus MCT[28d] and MCT[42d]) (Figure 3).
Chronic effects of aerosolized tolafentrine: survival
In this study, rats were randomized to receive vehicle or
inhaled tolafentrine beginning four weeks after MCT treat-
ment. In the MCT[28d] group a survival of 78% was noted,
while survival decreased to 60% in the MCT[42d] group. In
the MCT[42d]/Tola 80 % survived the treatment protocol.
However, due to insufficient number of experiments the
significant effects on this parameter were not shown in
detail.
Chronic effects of aerosolized tolafentrine: histopathology
Elastin staining and subsequent morphometric analysis of
pulmonary arteries demonstrated a markedly increased
medial wall thickness in both the MCT[28d]  and the
MCT[42d] groups, when compared with the saline-treated
group (Figure 4). In comparison to control animals, the
percentage of medial wall thickness of arteries sized
between external diameters of 25 to 50 µm was increased
significantly from 18.3 ± 0.42 to 28.5 ± 0.33 (MCT[28d])
and 29.1 ± 0.48 (MCT[42d]) (Figure 5A). To a similar
extent, the percentage of medial wall thickness of arteries
with external diameters of 51–100 µm increased from 17
± 0.49 (control) to 22.2 ± 0.31 (MCT[28d]) and 25.1 ± 0.77
(MCT[42d]) (Figure 5B). In arteries larger than 100 µm, the
corresponding data were 14.8 ± 0.95 (control), 18.1 ±
0.57 (MCT[28d]) and 20.6 ± 1.44 (MCT[42d]) (Figure 5C),
respectively. The evaluation of the extent of musculariza-
tion of pulmonary arteries with external diameters of 15
Effect of inhaled tolafentrine on medial wall thickness of pulmonary arteries Figure 5
Effect of inhaled tolafentrine on medial wall thickness of pulmonary arteries. Measurement of medial wall thickness 
(given in percentage of total wall thickness) of pulmonary arteries sized from (A) 25 to 50 µm, (B) 51–100 µm and (C) >101 
µm. All values are given as mean ± SEM. *, p < 0.05 versus control; †, p < 0.05 versus MCT[28d]; ‡, p < 0.05 versus MCT[42d].Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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to 50 µm demonstrated a significant reduction in non-
muscularized pulmonary arteries (62.6 ± 5.5% in con-
trols, 3.7 ± 2.1 % in MCT[28d], 1.6 ± 0.7 % in MCT[42d]).
Concomitantly, a significant increase in fully muscular-
ized vessels from 2.4 ± 0.62 (control) to 51.1 ± 6.85
(MCT[28d]) and 71.6 ± 2.63 (MCT[42d]) was noted (Figure
6).
Most impressively, both, medial wall thickness (22.5 ±
0.65%) and percentage of fully muscularized pulmonary
arteries (32.5 ± 5) were significantly reduced by long term
treatment of aerosolized tolafentrine, while the percent-
age of non-muscularized pulmonary arteries significantly
increased.
Comparison of migratory responses of control- and MCT-
PASMCs
Migration of control and MCT-treated rat PASMCs was
examined at 8 and 24 h in the presence of the chemo-
attractant PDGF-BB (Figure 7). In the presence of PDGF-
BB, the migration rate of PASMCs derived from MCT rats
ranged at 207% and 155% of that of the PASMCs derived
from control rats (8 hr and 24 hr data, respectively).
Effect of tolafentrine: PDGF-Induced MCT- PASMCs 
migration
Inhibitory effects of tolafentrine on MCT- treated rat PAS-
MCs migration were examined using a migration assay
with modified Boyden chamber. The PDGF caused strong
enhancement of PASMC migration. Treatment with tolaf-
entrine inhibited PDGF induced PASMC migration in a
dose-dependent fashion: at 0.05, 0.1, and 0.3 µM tolafen-
trine, PASMC migration was reduced by 34 %, 72 %, and
92 % (Figure 8).
Effects of tolafentrine: expression of matrix-degrading 
proteases
To study the mechanisms underlying tolafentrine-inhib-
ited PASMC migration, lung samples from control,
MCT[42d] and MCT[42d]/Tola rats were analyzed on 96 gene
arrays encoding key extracellular matrix and adhesion
molecules (representative arrays given in Figure 9). The
analysis shows expression of 12 of the 96 extracellular
matrix and adhesion related genes in the control lungs.
Further, a total of 12 genes were differentially expressed
and modulated in the MCT-treated lungs. The up-regu-
lated genes include 7 MMPs (MMP 2, MMP 8, MMP 9,
MMP 10, MMP 11, MMP 12, MMP 20), 1 serine protease
(Plat), 3 cell adhesion molecules (ICAM-1, NCAM-1,
Itgax), and 1 protease inhibitor (Serpinb2).
To validate these findings, the expression of 12 genes was
investigated by quantitative real-time PCR. These results
confirmed the array data for most of the proteases investi-
gated (Figure 10). Monocrotaline treatment for four
weeks caused an upregulation of the gelatinases MMP 2
and MMP 9 by a factor of 3.39 ± 0.65 and 3.92 ± 0.77,
Comparison of migratory responses of control and MCT –  PASMCs Figure 7
Comparison of migratory responses of control and 
MCT – PASMCs. Migratory responses of control and 
monocrotaline rat PASMCs were compared at different time 
points in presence of PDGF-BB (25 ng/ml). The number of 
migrated cells was counted in 5 random areas per mem-
brane. The results are based on three different independent 
experiments. All values are given as mean ± SEM. *, p < 0.05 
versus control PASMCs at the respective time points.
Effect of inhaled tolafentrine on the degree of musculariza- tion of peripheral pulmonary arteries Figure 6
Effect of inhaled tolafentrine on the degree of muscu-
larization of peripheral pulmonary arteries. Percent-
age of non- (N), partially (P) or fully (M) muscularized 
pulmonary arteries, related to the total number of pulmo-
nary arteries is given. A total of 60 to 80 intra-acinar vessels 
were analysed in each single lung from saline (Control), 
monocrotaline (MCT[28d] and MCT[42d]), and monocrotaline 
plus tolafentrine (MCT[42d]/Tola) treated animals. Tolafen-
trine was applied by repetitive inhalations from day 28 to day 
42. All values are given as mean ± SEM. *, p < 0.05 versus 
control; †, p < 0.05 versus MCT[28d]; ‡, p < 0.05 versus 
MCT[42d].Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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respectively. MMP 8, the interstitial collagenase, was ele-
vated 4.77 ± 1.44 fold with MCT treatment. In addition,
the stromelysins MMP 10, MMP 11, MMP 12 and MMP
20 were significantly upregulated by factors of 4.65 ± 1.13,
5.27 ± 1.03, 2.27 ± 0.63 and 6.67 ± 0.75, respectively.
Several adhesion molecules were also differentially
expressed at the mRNA level. We observed a significantly
increased expression of Icam and Itgax (4.34 ± 1.22 and
3.44 ± 0.33 fold). In contrast, Ncam was not changed
upon MCT treatment. An upregulation of tissue plasmino-
gen activator (plat) by 3.74 ± 0.83 and plasminogen acti-
vator inhibitor-2 (Serpinb2) by 2.68 ± 0.83 foldwith MCT
treatment was also observed.
Most impressively, virtually all alterations in extracellular
matrix and adhesion molecule gene expression induced
by monocrotaline were fully or partially abrogated by
tolafentrine (12 genes given in Figure 10).
Discussion
In the present study, we demonstrate that daily repetitive
tolafentrine inhalation significantly improved pulmonary
hemodynamics and reversed structural and molecular
changes underlying MCT induced PAH in rats. Notably,
the inhalative therapy was commenced after full establish-
ment of pulmonary hypertension, 4 weeks after applica-
tion of monocrotaline. Similar to the abnormalities in
human PAH, monocrotaline treatment in rats is known to
provoke endothelial injury, proliferation, migration and
hypercontraction of vascular smooth muscle cells, as well
as inflammatory sequelae [28,29]. The animals die due to
a progressive increase in precapillary lung vascular resist-
ance with subsequent right heart failure.
A recent study by our group showed that intravenous infu-
sion of the combined selective PDE 3/4 inhibitor (tolafen-
trine) prevented the development of pulmonary
hypertension and right ventricular hypertrophy in
response to monocrotaline [11]. However, the complexity
and complications associated with the intravenous appli-
cation of an agent exerting at the same time pulmonary
and systemic vasodilation prompted us to evaluate the
inhalative route of application in the present study. More-
over, the therapeutic potential of tolafentrine, i.e. its effi-
cacy after full establishment of severe pulmonary
hypertension, and its impact on molecular mechanisms
closely linked with the structural wall changes were not
addressed in the previous study.
For the inhalation therapy, aimed to achieve a selective
pulmonary vasodilation, a 15 fold lower dose compared
with the intravenous route of application was employed
(120 µg/kg day versus 2 mg/kg day). This low inhaled dos-
age exerted per se no acute effects on systemic hemody-
namics but demonstrated selective pulmonary
vasodilation as has been demonstrated for several other
compounds [16,17]. Further increase in dose results in
spill over of the compound in the systemic circulation and
systemic side effects as demonstrated by the higher dose of
650 µg tolafentrine/kg min in this study. Since PDE 3 and
4 are expressed in smooth muscle cells throughout the
cardiovascular system, tolafentrine was nebulized in a
dose which cause some direct lung vasorelaxation but
which is still too low to provoke systemic vasodilatory
effects. However, the results of an acute test of inhaled
tolafentrine under general anesthesia may not reproduce
the effects in an awake animal, but long term nebulization
demonstrated strong anti-remodeling effects in the setting
of MCT-induced PH.
Nevertheless, and notwithstanding the late initiation of
the tolafentrine treatment, hemodynamics were dramati-
cally improved after 2 weeks of inhalative tolafentrine
treatment: RVSP values were markedly lower than those
before onset of treatment, and cardiac index as well as
total pulmonary resistance index were also fully normal-
ized. Accordingly, the right heart hypertrophy was found
to be largely decreased, as were the structural changes of
the lung vasculature evoked by monocrotaline treatment.
The increase in the medial thickness of the precapillary
lung arteries was reversed, and the high percentage of fully
muscularized peripheral pulmonary arteries decreased in
Effect of tolafentrine on PDGF-directed PASMCs migration Figure 8
Effect of tolafentrine on PDGF-directed PASMCs 
migration. Tolafentrine at different concentrations (0.05, 
0.1, and 0.3 µM) inhibited PDGF-BB (25 ng/ml)-induced 
MCT-treated rat PASMCs migration. The number of 
migrated cells was counted in 5 random areas per mem-
brane. The results are based on three independent experi-
ments. All values are given as mean ± SEM. *, p < 0.05 versus 
PDGF-BB stimulated PASMCs.Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
Page 10 of 14
(page number not for citation purposes)
response to tolafentrine inhalation. To our knowledge,
this is the first time that combined selective PDE 3/4 inhi-
bition (tolafentrine) has been shown to reverse estab-
lished pulmonary hypertension both with respect to
hemodynamics and the structural remodeling of the lung
vasculature.
These findings suggest a potent anti-proliferative effect of
combined selective PDE 3/4 inhibition in the lung vascu-
lature, as has been suggested by preceding in vitro data.
Selective and nonselective cAMP PDE inhibitors have
been shown to elicit a concentration-dependent attenua-
tion of mitogen-induced proliferation in rat and human
PASMC predominantly via adenylyl cyclase and protein
kinase A [30,31]. Furthermore, PASMC receiving the com-
bination of a PDE3 and a PDE4 inhibitor exhibited a sig-
nificant additive or synergistic anti-mitogenic effect as
compared to each PDE inhibitor used on its own.
Interestingly, an enhanced migratory capacity in response
to PDGF was observed in PASMCs isolated form lungs of
MCT treated rats as compared to matched control lungs.
This is reminiscent of the reported higher migratory
response of aortic SMCs derived from spontaneously
hypertensive rats as compared to normotensive rats
[31,32]. Although the mechanisms responsible for the dif-
ferential migratory responses of SMC are not known,
increased collagenase activities might partly explain this
phenomenon, since the destruction of extracellular matrix
barriers is an important early step for SMC migration
[33,34]. Moreover, enhanced MAP kinase activities, such
as extracellular signal-regulated kinase (ERK) and p38
kinase [35], might play a role in PDGF-induced vascular
SMC migration, which is in line with the observation of
increased ERK expression in the precapillary arteries of
MCT-treated rats (data not shown).
The present study demonstrates for the first time that
selective PDE 3/4 inhibition inhibits the migration of
Effect of tolafentrine on MMP and adhesion molecule gene expression – cDNA micro-array analysis Figure 9
Effect of tolafentrine on MMP and adhesion molecule gene expression – cDNA micro-array analysis. Biotin 
labeled cDNA probes generated from total RNA from control lungs (Control), monocrotaline (MCT[42d]), and monocrotaline 
plus tolafentrine (MCT[42d]/Tola) treated lungs were hybridized to the identical extracellular matrix and adhesion molecules 
gene arrays. Hybridization patterns were assessed by chemiluminescence. Arrays representative of three independent array 
experiments per group are shown.Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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SMCs stimulated with PDGF in a concentration-depend-
ent manner. The PDGF-BB-induced SMC migration was
significantly inhibited by 0.05–0.3 µM tolafentrine. This
is well in line with the study of T. Horio et al, who
reported that adrenomedullin inhibits the migration of
aortic SMCs in response to PDGF, probably through a
cAMP-dependent process [36]. Downstream effects of ele-
vated cAMP levels, being relevant for the SMC migratory
response, may include MAP kinase signaling and cytosolic
Ca2+ regulation [37,38].
The anti-proliferative and anti-migratory effects of tolaf-
entrine may be closely linked to matrix regulation. Our
group and others have previously demonstrated an
increased expression of gelatinases, MMP 2 and MMP 9 in
monocrotaline induced pulmonary hypertension [5,11].
In order to approach this field in more depth, gene array
analysis of proteinases and adhesion molecules and sub-
sequent confirmation with real time PCR was undertaken
in the present study. A strong upregulation of various
extracellular matrix and adhesion molecule genes in
response to monocrotaline was noted, in particular MMPs
(MMP 2, 8, 9, 10, 11, 12, 20), serine proteases (Plat and
Serpinb2) and cell adhesion molecules (Icam, Ncam and
Itgax). These observations strongly support the notion
that increased MMP expression and activity directly corre-
lates with the severity of disease in various experimental
forms of pulmonary hypertension. Several mechanisms
may be responsible for MMP upregulation in pulmonary
arteries during PAH (Figure 11). The MMP expression may
Quantitative real-time RTPCR confirmation of relative changes detected in micro arrays Figure 10
Quantitative real-time RTPCR confirmation of relative changes detected in micro arrays. Relative quantification 
of mRNAs encoding for MMP 2, MMP 8, MMP 9, MMP 10, MMP 11, MMP 12, MMP 20, Icam, Itgax, Ncam, Plat, and Serpinb2 
related to the housekeeping gene GAPDH was undertaken by real-time RTPCR. The lung samples originated from control, 
monocrotaline (MCT[42d]), and monocrotaline plus tolafentrine (MCT[42d]/Tola) treated animals. All values are given as mean ± 
SEM. *, p < 0.05 versus control, †, p < 0.05 versus MCT[42d].Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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be stimulated by growth factors (PDGF, EGF), cytokines,
most notably interleukin IL-1α, and physical forces,
which may be induced after MCT administration. Several
of these factors stimulate a cascade of MAP kinases and
PKC and potently activate the transcription factors AP-1
and NF-kB, which are involved in MMP and adhesion
molecule expression [39,40]. Most notably, tolafentrine
treatment resulted in strong down-regulation or even nor-
malization of the transcription of most of the MMP and
adhesion molecule genes that were upregulated in
response to MCT. Moreover, the inhibitory effect of tolaf-
entrine on MMPs was functionally confirmed, since it sig-
Potential interactions among various mediator pathways in the regulation of MMP expression and in the subsequent develop- ment of PH Figure 11
Potential interactions among various mediator pathways in the regulation of MMP expression and in the sub-
sequent development of PH. Schematic depiction of molecular mechanisms responsible for MMP transcriptional regulation. 
Growth factors such as tyrosine kinases (TK), endothelin system (ET) and serine elastases (S.Elastases) positively modulate 
several MMP genes transcription. MMPs that were produced then cleave extracellular matrix (ECM) and thereby promotes 
SMC migration and proliferation. Augmentation of these processes ultimately leads to pulmonary vascular remodeling and PH. 
In contrast, mediators that influence cAMP pathway (Prostacyclin analogues (PGI2) and combined PDE 3/4 inhibitors (tolafen-
trine) and to a less extent nitric oxide (NO) represses MMP gene activation that were positively modulated by various growth 
factors during development of PH. These effects eventually lead to regression of matrix degradation, SMC migration and prolif-
eration and reverse-remodeling of pulmonary arteries. GF, growth factor; TK, tyrosine kinase; MEK, MAP/ERK kinase; ERK, 
Extracellular signal-regulated kinase; IP, prostaglandin I2 (prostacyclin) receptor; AC, adenylyl cyclase; PDE3, phosphodieste-
rase isoenzyme 3; PDE4, phosphodiesterase isoenzyme 4; iPKA, inhibitory protein kinase A; aPKA, activated protein kinase A; 
S.Elastases, serine elastases; NO, nitric oxide; ATF3, activating transcription factor 3; ET, endothelin; ETR, endothelin receptor; 
AP1, activator protein 1; CREB, CRE-binding protein; NFkβ, Sp1, Sp1, transcription factor; NF-kB, nuclear factor-kappaB (p65); 
MMP, matrix metallo proteases; ECM, extracellular matrix.Respiratory Research 2005, 6:128 http://respiratory-research.com/content/6/1/128
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nificantly reduced the migratory properties of PASMCs in
vitro. This most impressive regression of MMP and adhe-
sion molecule expression under tolafentrine may in part
be explained by cAMP-mediated regulation of cytokines
and growth factors, being upstream effectors of MMPs
(Figure 11). In addition, cAMP has been shown to inhibit
the NF-kB transcriptional activity via protein kinase A [41-
43]. Such impact might also explain the down-regulation
of Icam and Ncam by tolafentrine, as these adhesion mol-
ecules are also known to be NF-kB dependent [44].
Conclusion
In conclusion, we demonstrate for the first time that inha-
lation of a combined selective PDE3/4 inhibitor reverses
pulmonary hypertension fully developed in response to
monocrotaline in rats. This "reverse-remodeling" effect
was true for hemodynamics, structural changes to the lung
vascular wall, and key molecular pathways of matrix regu-
lation. We provide evidence that inhibition of pulmonary
artery SMC migration and MMP-based matrix regulation
play a major role in the beneficial effect of inhaled tolaf-
entrine in severe PAH. Reversal of structural lung vascular
remodeling may apparently be achieved in pulmonary
hypertension, at least in the experimental model of
monocrotaline-induced PAH in rats.
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